Agenus (AGEN) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Agenus (AGEN) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 80.5% versus a loss of 15.2%. Over five years, AGEN leads with a -92.6% price change compared with -98.1% for XFOR. Agenus is the larger company by market cap ($346.4 million vs $288.5 million), about 1.2 times the size.
On valuation, Agenus trades at a lower trailing P/E (3.0x vs 145.5x for X4 Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | XFOR |
|---|---|---|
| Share price | $7.67 | $2.91 |
| Market cap | $346.39M | $288.52M |
| 1-day change | +1.72% | +4.30% |
| YTD return | +144.27% | -27.25% |
| 1-year return | +80.47% | -15.16% |
| 5-year return | -92.64% | -98.15% |
| P/E ratio (TTM) | 3.03 | 145.50 |
| EPS (TTM) | $2.53 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $4.83 |
| 52-week low | $2.71 | $2.70 |
| Distance from 52-week high | -25.61% | -39.75% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +243.29% | +298.63% |
| Average volume | 4.26M | 843.69K |
| Shares outstanding | 45.16M | 99.15M |
| Employees | 81 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed XFOR by 95.6 percentage points over the past year.
- X4 Pharmaceuticals trades at a higher earnings multiple (145.5x vs 3.0x trailing P/E).
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
AGEN vs XFOR FAQ
Which is bigger, Agenus or X4 Pharmaceuticals?
Agenus (AGEN) is larger, with a market capitalization of $346.39M compared with $288.52M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, AGEN or XFOR?
AGEN returned +80.47% over the past 12 months, compared with -15.16% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AGEN or XFOR?
AGEN has the lower trailing P/E at 3.0, versus 145.5 for XFOR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Agenus and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.